Greenwich LifeSciences (NASDAQ:GLSI) has announced the launch of two new clinical sites for its FLAMINGO-01 Phase 3 trial of GLSI-100 in HER2 breast cancer, including Harvard and Johns Hopkins Universities.
Additionally, the company announced that two new principal investigators, Dr. Laura Spring and Dr. Cesar Santa-Maria, will join the steering committee, which is comprised of international experts in the field of breast cancer oncology.
Dr. Laura Spring, is a clinical/translational investigator and breast cancer oncologist at the Massachusetts General Hospital Cancer Center. Dr. Cesar Santa-Maria is a board-certified medical oncologist, and associate professor of oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and director of breast clinical trials in the Breast and Gynecological Malignancies Disease Group.
In a statement, Dr. Jaye Thompson, VP clinical and regulatory affairs at Greenwich, said, “Greenwich is honored to be working with a stellar collection of clinical trial sites around the globe. The institutions, represented by Dr. Spring and Dr. Santa-Maria, exhibit the caliber of sites participating in FLAMINGO-01.”
Dr. Spring commented, “We are excited to offer the FLAMINGO-01 trial at MGH for patients with high-risk HER2-positive breast cancer. There is high patient and physician interest in vaccine strategies to reduce recurrence risk.”
Dr. Santa-Maria commented, “I am thrilled to be opening the FLAMINGO-01 at Johns Hopkins and offering this study for our patients with high-risk HER2-positive breast cancer. A vaccine approach is particularly well suited to this patient population who have completed standard therapy, as risk still remains, and secondary prevention strategies are urgently needed.”
